Accès gratuit
Numéro
Med Sci (Paris)
Volume 29, Numéro 1, Janvier 2013
Page(s) 83 - 88
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2013291017
Publié en ligne 25 janvier 2013
  1. Cohen EE. Novel therapeutic targets in squamous cell carcinoma of the head and neck. Semin Oncol 2004 ; 31 : 755–768. [CrossRef] [PubMed] [Google Scholar]
  2. Syrjanen K, Syrjanen S, Lamberg M, et al. Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J Oral Surg 1983 ; 12 : 418–424. [CrossRef] [PubMed] [Google Scholar]
  3. Ryerson AB, Peters ES, Coughlin SS, et al. Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998–2003. Cancer 2008 ; 113 : 2901–2909. [CrossRef] [PubMed] [Google Scholar]
  4. Hansson BG, Rosenquist K, Antonsson A, et al. Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden. Acta Otolaryngol 2005 ; 125 : 1337–1344. [CrossRef] [PubMed] [Google Scholar]
  5. Syrjanen S. The role of human papillomavirus infection in head and neck cancers. Ann Oncol 2010 ; 21 : vii243–vii245. [CrossRef] [PubMed] [Google Scholar]
  6. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008 ; 26 : 612–619. [CrossRef] [PubMed] [Google Scholar]
  7. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005 ; 14 : 467–475. [CrossRef] [PubMed] [Google Scholar]
  8. Dayyani F, Etzel CJ, Liu M, et al. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk, overall survival in head, neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2010 ; 2 : 15. [CrossRef] [PubMed] [Google Scholar]
  9. St Guily JL, Jacquard AC, Pretet JL, et al. Human papillomavirus genotype distribution in oropharynx and oral cavity cancer in France - The EDiTH VI study. J Clin Virol 2011 ; 51 : 100–104. [CrossRef] [PubMed] [Google Scholar]
  10. Hocking JS, Stein A, Conway EL, et al. Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers. Br J Cancer 2011 ; 104 : 886–891. [CrossRef] [PubMed] [Google Scholar]
  11. Si-Mohamed A, Badoual C, Hans S, et al. An unusual human papillomavirus type 82 detection in laryngeal squamous cell carcinoma: case report and review of literature. J Clin Virol 2012 ; 54 : 190–193. [CrossRef] [PubMed] [Google Scholar]
  12. D’Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007 ; 356 : 1944–1956. [CrossRef] [PubMed] [Google Scholar]
  13. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA 2012 ; 307 : 693–703. [CrossRef] [PubMed] [Google Scholar]
  14. Chen R, Sehr P, Waterboer T, et al. Presence of DNA of human papillomavirus 16 but no other types in tumor-free tonsillar tissue. J Clin Microbiol 2005 ; 43 : 1408–1410. [CrossRef] [PubMed] [Google Scholar]
  15. Duray A, Descamps G, Bettonville M, et al. High prevalence of high-risk human papillomavirus in palatine tonsils from healthy children and adults. Otolaryngol Head Neck Surg 2011 ; 145 : 230–235. [CrossRef] [PubMed] [Google Scholar]
  16. Chernock RD, Lewis JS, Jr, Zhang Q, El-Mofty SK. Human papillomavirus-positive basaloid squamous cell carcinomas of the upper aerodigestive tract: a distinct clinicopathologic and molecular subtype of basaloid squamous cell carcinoma. Hum Pathol 2010 ; 41 : 1016–1023. [CrossRef] [PubMed] [Google Scholar]
  17. Thariat J, Badoual C, Faure C, et al. Basaloid squamous cell carcinoma of the head and neck: role of HPV and implication in treatment and prognosis. J Clin Pathol 2010 ; 63 : 857–866. [CrossRef] [PubMed] [Google Scholar]
  18. Shi W, Kato H, Perez-Ordonez B, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 2009 ; 27 : 6213–6221. [CrossRef] [PubMed] [Google Scholar]
  19. Shoushtari AN, Rahimi NP, Schlesinger DJ, Read PW. Survey on human papillomavirus/p16 screening use in oropharyngeal carcinoma patients in the United States. Cancer 2010 ; 116 : 514–519. [CrossRef] [PubMed] [Google Scholar]
  20. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008 ; 100 : 261–269. [CrossRef] [PubMed] [Google Scholar]
  21. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 2008 ; 26 : 3138–3146. [CrossRef] [PubMed] [Google Scholar]
  22. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010 ; 363 : 24–35. [CrossRef] [PubMed] [Google Scholar]
  23. Maxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res 2010 ; 16 : 1226–1235. [CrossRef] [PubMed] [Google Scholar]
  24. Duray A, Descamps G, Decaestecker C, et al. Human papillomavirus DNA strongly correlates with a poorer prognosis in oral cavity carcinoma. Laryngoscope 2012 ; 122 : 1558–1565. [CrossRef] [PubMed] [Google Scholar]
  25. Rosenquist K, Wennerberg J, Annertz K, et al. Recurrence in patients with oral and oropharyngeal squamous cell carcinoma: human papillomavirus and other risk factors. Acta Otolaryngol 2007 ; 127 : 980–987. [CrossRef] [PubMed] [Google Scholar]
  26. Klingenberg B, Hafkamp HC, Haesevoets A, et al. p16 INK4A overexpression is frequently detected in tumour-free tonsil tissue without association with HPV. Histopathology 2010 ; 56 : 957–967. [CrossRef] [PubMed] [Google Scholar]
  27. Badoual C, Sandoval F, Pere H, et al. Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head Neck 2010 ; 32 : 946–958. [PubMed] [Google Scholar]
  28. Albers A, Abe K, Hunt J, et al. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 2005 ; 65 : 11146–11155. [CrossRef] [PubMed] [Google Scholar]
  29. Hoffmann TK, Arsov C, Schirlau K, et al. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer 2006 ; 118 : 1984–1991. [CrossRef] [PubMed] [Google Scholar]
  30. Heusinkveld M, Welters MJ, van Poelgeest MI, et al. The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors. Int J Cancer 2011 ; 128 : 379–389. [CrossRef] [PubMed] [Google Scholar]
  31. Thurlow JK, Pena Murillo CL, Hunter KD, et al. Spectral clustering of microarray data elucidates the roles of microenvironment remodeling and immune responses in survival of head and neck squamous cell carcinoma. J Clin Oncol 2010 ; 28 : 2881–2888. [CrossRef] [PubMed] [Google Scholar]
  32. Kong CS, Narasimhan B, Cao H, et al. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2009 ; 74 : 553–561. [CrossRef] [PubMed] [Google Scholar]
  33. Rincon-Orozco B, Halec G, Rosenberger S, et al. Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells. Cancer Res 2009 ; 69 : 8718–8725. [CrossRef] [PubMed] [Google Scholar]
  34. Koromilas AE, Li S, Matlashewski G. Control of interferon signaling in human papillomavirus infection. Cytokine Growth Factor Rev 2001 ; 12 : 157–170. [CrossRef] [PubMed] [Google Scholar]
  35. Badoual C, Bouchaud G, Agueznay Nel H, et al. The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. Cancer Res 2008 ; 68 : 3907–3914. [CrossRef] [PubMed] [Google Scholar]
  36. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012 ; 13 : 89–99. [CrossRef] [PubMed] [Google Scholar]
  37. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009 ; 361 : 1838–1847. [CrossRef] [PubMed] [Google Scholar]
  38. Daayana S, Elkord E, Winters U, et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer 2010 ; 102 : 1129–1136. [CrossRef] [PubMed] [Google Scholar]
  39. Welters MJ, Kenter GG, van Steenwijk PJ, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci USA 2010 ; 107 : 11895–11899. [CrossRef] [Google Scholar]
  40. Berraondo P, Nouze C, Preville X, et al. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 2007 ; 67 : 8847–8855. [CrossRef] [PubMed] [Google Scholar]
  41. Pere H, Montier Y, Bayry J, et al. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 2011 ; 118 : 4853–4862. [CrossRef] [PubMed] [Google Scholar]
  42. Van der Burg SH, Melief CJ. Therapeutic vaccination against human papilloma virus induced malignancies. Curr Opin Immunol 2011 ; 23 : 252–257. [CrossRef] [PubMed] [Google Scholar]
  43. Silbermann B, Launay O. Prévention des infections à papillomavirus et du zona : nouveaux vaccins. Med Sci (Paris) 2007 ; 23 : 423–427. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.